Xin Lang Cai Jing·2025-09-16 02:43Core Insights - Junshi Bioscience's stock price has increased by 70.07% year-to-date, but has seen a decline of 3.69% over the past five trading days [2] - The company reported a revenue of 1.168 billion yuan for the first half of 2025, representing a year-on-year growth of 48.64% [2] - The net profit attributable to shareholders for the same period was -413 million yuan, showing a year-on-year increase of 36.01% [2] Company Overview - Junshi Bioscience, established on December 27, 2012, is located in Shanghai and specializes in the research and commercialization of monoclonal antibody drugs and other therapeutic protein drugs [2] - The company's main revenue sources are drug sales (90.67%), technology licensing and royalties (8.74%), and technical services (0.59%) [2] - As of June 30, 2025, the company had 31,200 shareholders, an increase of 5.88% from the previous period [2] Stock Performance - As of September 16, the stock price was 46.48 yuan per share, with a market capitalization of 47.721 billion yuan [1] - The trading volume on September 16 was 305 million yuan, with a turnover rate of 0.85% [1] - The net outflow of main funds was 18.4435 million yuan, with large orders showing a buy of 86.9331 million yuan and a sell of 95.7846 million yuan [1] Institutional Holdings - As of June 30, 2025, the top ten circulating shareholders included Huaxia SSE Sci-Tech Innovation Board 50 ETF, which held 29.7167 million shares, a decrease of 536,700 shares from the previous period [3] - E Fund SSE Sci-Tech Innovation Board 50 ETF increased its holdings to 22.2132 million shares, an increase of 630,000 shares [3] - Hong Kong Central Clearing Limited held 13.1291 million shares, a decrease of 186,650 shares [3]